Early Access — free while we kick the tires
EdgarHawk

Kelsey Stephen Michael

See Remarks

Officer
2 filings analyzed · 1 company · Latest 2025-10-15

Companies

Company Buys Sells Direction
Revolution Medicines, Inc. RVMD 0 8 Net selling

Activity

October 2025
medium
Sell
25,000 shares
$1,213,540
Significance 6/10

CFO Kelsey Stephen Michael sold 25,000 RVMD shares at $48.54 on 2025-10-13 ($1.2M); retains 284.0K shares post-sale.

Kelsey Stephen Michael sold 25,000 shares at $48.54, reducing holdings by 8.1% to 284,047 shares. At the prior trade on 2025-09-15, the insider's two sales generated 30-day returns of +7.9% and +5.6%, consistent with a pattern: his cross-ticker track record shows 100.00% well-timed rate on 6 prior sells with an average 90-day return of -38.0%, indicating he historically sells before downturns. The stock has risen +7.3% over the past 30 days since this sale, contrasting with his average post-sale performance. RVMD is unprofitable with quarterly revenue of $0.00 and full-year net income of $-247,787,000.00; the stock currently trades 18.2% below its 52-week high of $60.60. The sale itself reflects moderate confidence reduction and warrants observation of whether this transaction aligns with the insider's prior timing acumen or signals a departure.

September 2025
high
Sell
125,000 shares
$5,557,754
Significance 6/10

SVP sells 125,000 shares (30.2% reduction) for $5,557,754.29 at RVMD; prior two trades well-timed at 90-day mark.

Kelsey Stephen Michael sold 125,000 shares across 4 transactions on September 11 and 15, 2025, reducing his holdings from 414,414 to 289,414 shares at a blended average price of $44.46. The stock currently trades at $46.20, only slightly above the transaction prices, but the timing context is notable: his prior two sales at RVMD in August 2023 both proved well-timed at the 90-day mark (returns of -38.9% and -37.1% respectively), suggesting a pattern of selling before downturns at this ticker. This latest sale comes after a 30-day rally of +27.2%, near the 52-week high of $60.60 (currently -23.8% below that peak), and the company remains unprofitable with zero latest-quarter revenue and a full-year net loss of $247,787,000.00. The sale's significance lies not in the absolute dollar amount but in the 30% reduction of holdings combined with the documented timing pattern in prior same-ticker trades.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access